Potent Activity of Carfilzomib, a Novel, Irreversible Inhibitor of the Ubiquitin-proteasome Pathway, Against Pre-clinical Models of Multiple Myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijs W.B. van Leeuwen, Asher A. Chanan-Khan, and Robert Z. Orlowski

The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology and the Department of Pharmacology, Chapel Hill, NC; Proteolix, Inc., South San Francisco, CA; The Netherlands Cancer Institute, Division of Cellular Biochemistry, Amsterdam, the Netherlands; and the Roswell Park Cancer Institute, Department of Medicine, Buffalo, NY.

Address correspondence to: Dr. Robert Z. Orlowski, The University of North Carolina at Chapel Hill, 22-003 Lineberger Comprehensive Cancer Center, CB # 7295, 450 West Drive, Chapel Hill, NC 27599-7295, E-mail R_Orlowski@med.unc.edu, Telephone 919-966-9762, FAX 919-966-8212
Abstract

The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). However, many patients have disease that does not respond to bortezomib, while others develop resistance, suggesting the need for other inhibitors with enhanced activity, and we therefore evaluated a novel, irreversible, epoxomicin-related proteasome inhibitor, carfilzomib. In models of MM, this agent potently bound and specifically inhibited the chymotrypsin-like proteasome and immunoproteasome activities, resulting in accumulation of ubiquitinated substrates. Carfilzomib induced a dose- and time-dependent inhibition of proliferation, ultimately leading to apoptosis. Programmed cell death was associated with activation JNK, mitochondrial membrane depolarization, release of cytochrome c, and activation of both intrinsic and extrinsic caspase pathways. This agent also inhibited proliferation and activated apoptosis in patient-derived MM cells, as well as neoplastic cells from patients with other hematologic malignancies. Importantly, carfilzomib showed increased efficacy compared to bortezomib, and was active against bortezomib-resistant MM cell lines, and samples from patients with clinical bortezomib resistance. Carfilzomib also overcame resistance to other conventional agents, and acted synergistically with dexamethasone to enhance cell death. Taken together, these data provide a rationale for the clinical evaluation of carfilzomib in MM.
Introduction

The 26S proteasome plays a critical role in cellular homeostasis through its function in ubiquitin-dependent protein turnover, including targets involved in cell cycle progression, apoptosis, DNA repair, stress response, and misfolded and obsolete proteins. Major catalytic activities of the 20S core of the proteasome include a chymotrypsin-like (ChT-L) activity found in the β5 subunit, a trypsin-like activity (T-L) in subunit β2, and a post-glutamyl peptide hydrolyzing (PGPH), or caspase-like activity in the β1 subunit. Of these, the ChT-L activity has been shown to be the rate-limiting step of proteolysis in vitro and in vivo. Two major isoforms of the proteasome have been described, including the constitutive proteasome, which is present in most cells, and the immunoproteasome, which in place of the above subunits incorporates three related proteins termed β1i, β2i, and β5i. The immunoproteasome is predominately expressed in cells of lymphoid origin, and plays a role in major histocompatibility complex class I antigen presentation, and other constitutive proteolytic activities.

Bortezomib (VELCADE®) is the first proteasome inhibitor to enter clinical practice for the treatment of relapsed/refractory multiple myeloma (MM), based in part on pioneering preclinical studies. Phase I-III trials showed bortezomib had impressive anti-myeloma activity, and additional studies are ongoing to define its role in that disease, as well as in other hematologic malignancies such as non-Hodgkin lymphoma. However, the overall response rate from the phase III experience was 43%, and bortezomib resistance is emerging as well, underscoring the need for a next generation of proteasome inhibitors with greater efficacy. One such inhibitor is NPI-0052, or salinosporamide A, a compound related to lactacystin that showed anti-tumor activity predominantly through caspase-8 activation. Since lactacystin
binds to several proteasome subunits, however, and may inhibit other cellular proteases\textsuperscript{14}, this class of agents may be less specific. In contrast, epoxomicin is a natural product isolated from an \textit{Actinomycetes}\textsuperscript{15} that forms an irreversible, selective, and highly specific morpholino adduct only with the N-terminal threonine of the $\beta_5$ subunit.\textsuperscript{16} Since the activity of this class of inhibitors against MM has not been well studied, it was of interest to evaluate the effects of carfilzomib (formerly PR-171; Proteolix, Inc.), an epoxyketone related to epoxomicin (Fig. 1A).

In the current work, we demonstrate that carfilzomib inhibited the ChT-L activity of the proteasome both \textit{in vitro} and \textit{in cellulo} in models of MM. Experiments modeling the anticipated \textit{in vivo} pharmacokinetics of drug exposure showed that carfilzomib inhibited proliferation in a variety of cell lines and patient-derived neoplastic cells, including MM, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Furthermore, carfilzomib showed enhanced anti-MM activity compared with bortezomib, overcame resistance to bortezomib as well as other agents, and acted synergistically with dexamethasone. Taken together, these data indicate that carfilzomib is a promising proteasome inhibitor with activity against MM, providing a rational basis for its translation into the clinic.
Methods

Materials. The proteasome inhibitor bortezomib was obtained from the University of North Carolina at Chapel Hill pharmacy, while carfilzomib was provided by Proteolix, Inc. Stock solutions were prepared in dimethyl-sulfoxide and used as indicated in the text, with a final vehicle concentration that did not exceed 0.5% (v/v). All chemicals, unless otherwise indicated, were from Fisher Scientific.

Cell models, cell culture, and experimental conditions. RPMI 8226, U266, ANBL-6, KAS-6/1, H-929, 8226.Dox40, 8226.LR5, MM1.S, MM1.R, bortezomib-resistant (BR) cells, and patient-derived cells were cultured in RPMI 1640 (Invitrogen; Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma; St. Louis, MO), 100 U/ml penicillin, and 100 µg/ml streptomycin (Tissue Culture Facility; University of North Carolina at Chapel Hill), and maintained in 5% CO2 at 37°C. Interleukin (IL)-6-dependent cells and purified plasma cells from patients were supplemented with an additional 1 ng/ml of IL-6 (R&D Systems; Minneapolis, MN).

Patient samples were collected under a protocol approved by the Institutional Review Board of the University of North Carolina at Chapel Hill. Informed consent was provided in accordance with the Declaration of Helsinki Protocol. Mononuclear cells from bone marrow aspirates or peripheral blood samples were isolated by density gradient centrifugation over Ficoll-Paque Plus (Amersham Biosciences Corp.; Piscataway, NJ). Malignant cells were then isolated by immunomagnetic bead positive selection in a Midi MACS LS column following the manufacturer’s protocol (Miltenyi Biotec; Auburn, CA). The purity of MM cells was confirmed by flow cytometric analysis using phycoerythrin-conjugated anti-CD138 antibody (Miltenyi Biotec).
Cells in culture were exposed to proteasome inhibitors either in a continuous fashion, or in a discontinuous one designed to mimic the known pharmacokinetics of bortezomib in vivo, which is rapidly cleared from the circulation with a $t_{1/2\alpha}$ of 0.22 to 0.46 hours. In the latter, proteasome inhibitors were added for 1 hour, after which cultures were washed once with phosphate-buffered saline (PBS), and resuspended in drug-free media.

**Measurement of 20S proteasome activity.** In vitro measurements of catalytic 20S proteasome activities were performed as previously described.

**ELISA for subunit profiling of carfilzomib.** ANBL-6 cells (2 x $10^6$/well) were plated in 96-well plates and treated with carfilzomib doses from 0.001-10 µM for 1 hour. Cells were then lysed (20 mM Tris-HCl, 0.5 mM EDTA), and cleared lysates were transferred to PCR plates. A standard curve was generated using untreated ANBL-6 cell lysates starting at a concentration of 6 µg protein/µl. The active site probe (biotin-(CH$_2$)$_4$-Leu-Leu-Leu-epoxyketone; 20 µM) was added and incubated at room temperature for 1 hour. Cell lysates were then denatured by adding 1% SDS and heating to 100°C, followed by mixing with 20 µl/well streptavidin-sepharose high performance beads (GE Healthcare; Chalfont St. Giles, United Kingdom) in a 96-well multiscreen DV plate (Millipore; Billerica, MA) and incubated for 1 hour. These beads were then washed with ELISA buffer (PBS, 1% bovine serum albumin, 0.1% Tween-20), and incubated overnight at 4°C on a plate shaker with antibodies to proteasome subunits. Antibodies used included mouse monoclonal anti-β1, anti-β2, anti-β1i, and anti-β5i from Biomol (Plymouth Meeting, PA), goat polyclonal anti-β2i (Santa Cruz Biotechnology; Santa Cruz, CA), and rabbit polyclonal anti-β5 (affinity purified antiserum.
against KLH-CWIRVSSDNVADLHDKYS peptide). The beads were washed and incubated for 2 hours with horseradish peroxidase-conjugated secondary goat anti-rabbit, goat anti-mouse (Biosource; Camarillo, CA), or rabbit anti-goat (Invitrogen) antibodies. After washing, the beads were developed using the supersignal ELISA pico-chemiluminescence substrate (Pierce; Rockford, IL). Luminescent detection was performed on the Tecan Genius Pro (Mannedorf; Zurich, Switzerland). Raw luminescence was converted to µg/ml by comparison with the standard curve and expressed as the % inhibition relative to vehicle control. Curve fits were generated using the following non-sigmoidal dose response equation: Y=Bottom+(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)) where X is the logarithm of concentration and Y is the % inhibition.

**Competitive binding for subunit profiling of carfilzomib.** The protocol used to determine carfilzomib subunit specificity via competitive binding was adapted from Berkers et al.\(^\text{19}\) Briefly, ANBL-6 cells were preincubated with increasing carfilzomib doses at 37°C, followed by addition of the hapten-labeled cell-permeant vinyl sulfone proteasome inhibitor VS-L3-AHx3-dansyl. Western blots were then prepared as detailed below, and probed with polyclonal anti-dansyl antibodies (Invitrogen).

**Cell extract preparation and Western blotting.** Whole cell extracts were prepared and separated by denaturing gel electrophoresis as described previously.\(^\text{20}\) The antibodies used for immunoblotting included anti-Actin, anti-JNK, anti-Ubiquitin, and rat secondary antibodies (Santa Cruz Biotechnology), anti-Bax, anti-p-JNK (Thr138/Tyr185) and anti-PARP (EMD Biosciences; San Diego, CA), anti-HSC-70 and anti-Smac antibodies (Stressgen; San Diego, CA), anti-mouse secondary (Amersham Biosciences), anti-rabbit secondary (Bio-Rad;
Hercules, CA), anti-cytochrome c (Biovision, Inc.; Mountain View, CA) and anti-Cox II (Invitrogen).

**Cell proliferation assay.** WST-1 (Roche Diagnostics; Indianapolis, IN) was used to determine the effects of proteasome inhibitors on cell proliferation according to the manufacturer’s protocol. The inhibition of proliferation was calculated in relation to parallel control cells that received vehicle alone, and tabulated in KaleidaGraph 3.0.1 (Synergy Software; Reading, PA) or Excel 2000 (Microsoft®; Redmond, WA). A linear spline function was used to interpolate the median inhibitory concentration (IC$_{50}$) using XLfit 4 software (ID Business Solutions; Guildford, England). The degree of resistance was calculated using the formula: Degree of Resistance (DOR)=IC$_{50}$(resistant cells)/IC$_{50}$(sensitive cells).

**Apoptotic DNA fragmentation assay.** For apoptosis experiments, cells were seeded onto 96-well plates, treated with a 1 hour pulse of 300 nM (RPMI 8226, ANBL-6) or 100 nM carfilzomib (KAS-6/1, U266), and allowed to recover for 24 hours prior to analysis with the Cell Death Detection ELISA$^{PLUS}$ kit (Roche Diagnostics) according to the manufacturer’s specifications. The fold increase in DNA fragmentation is presented as the mean relative to vehicle-treated control cells.

**Mitochondrial membrane potential (ΔΨm).** ANBL-6 cells pulsed with 100 nM carfilzomib were washed and suspended in PBS containing 5 µg/ml of JC-1 (Invitrogen), which exhibits potential-dependent accumulation in mitochondria. Analysis of the mitochondrial membrane potential-dependent color shift from 525 nm to 590 nm was carried out on FacScan (Becton-Dickson; Franklin Lakes, NJ) and the data were analyzed using CellQuest software.
**Caspase activation assay.** Cellular lysates were incubated in Tris-HCl with 40 μM fluorogenic substrates from Biomol specific for caspase-3, -8, or -9. Measurement of free AMC groups was performed at 380/460 nm on a multilabel FLUOstar Optima (BMG Labtech; Durham, NC). Results were expressed as fold activation over the vehicle control from experiments performed in triplicate.

**Infection with recombinant adenovirus.** Recombinant adenoviruses carrying the dominant-negative (DN) c-Jun (TAM67 mutant) were from Vector Biolabs (Philadelphia, PA). ANBL-6 cells were incubated in medium containing the adenovirus carrying DN-c-Jun or an empty CMV promoter at a multiplicity of infection of 1000 for 24 hours at 37°C.

**Apoptosis detection with Annexin V and TO-PRO-3.** Staining of cells by Annexin V was performed according to the manufacturer’s specifications (BioVision, Inc.), while TO-PRO-3 was used to identify necrotic or late-stage apoptosis. Data were collected using CellQuest software on a FacsCalibur (Becton-Dickson; Franklin Lakes, NJ), and 10,000 events were analyzed using FlowJo v.6.3.3 (Tree Star, Inc.; Ashland, OR). Results are expressed as percentage specific apoptosis and were calculated using the following formula: \[\frac{((\% \text{ apoptotic cells in experimental} – \% \text{ apoptotic cells in control})/(100 – \% \text{ apoptotic cells in control}) \times 100}.\]
Results

Impact of carfilzomib on the constitutive and immunoproteasome.

Carfilzomib is a tetrapeptide epoxyketone related to epoxomicin (Fig. 1A), the latter of which shows high specificity in vitro for the ChT-L proteasome activity. To evaluate the proteasomal inhibitory potential of carfilzomib in MM, extracts from ANBL-6 cells were exposed to increasing concentrations of carfilzomib (Fig. 1B) and assayed for 20S catalytic activities. Carfilzomib displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM and above (Fig. 1B), and little or no effect on the PGPH and T-L activities at doses up to 100 nM. It has been reported that binding of proteasome inhibitors can differ in vitro and in live cells (in cellulo), so it was of interest to determine if carfilzomib interacted with other catalytic subunits in cellulo using an ELISA designed to identify subunit binding. This assay demonstrated that short exposure to low dose carfilzomib led to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits (Fig. 1C). However, at very high concentrations of >1 µM, carfilzomib did interact with the β1 and β2 subunits, as well as β1i and β2i. To confirm the subunit specificity of carfilzomib in another assay, a competitive binding technique was performed with a dansyl-linked peptide vinyl-sulfone inhibitor (VS-L3-AHx3-dansyl), which binds to free catalytic subunits and can be detected by Western blotting. Extended exposure to carfilzomib for 5 hours saturated the β5 and β5i active sites in a dose-dependent manner, and also led to increased binding to the β1, β1i, β2, and β2i subunits, with maximal binding observed at 50 nM (Fig. 1D). To mimic the in vivo pharmacokinetics of proteasome inhibitor treatment, RPMI 8226 cells were pulsed with carfilzomib for 1 hour, and then allowed to recover in drug-free media. Accumulation of ubiquitin-conjugated proteins was observed up to
48 hours after recovery from the pulse (Fig. 1E). Additionally, the accumulation of pro-apoptotic Bax, a proteasome target, was also observed at 24 and 48 hours after treatment, signifying a potent and durable proteasome inhibition by carfilzomib (Fig. 1F).

**Anti-proliferative and pro-apoptotic impact of carfilzomib.** To determine if carfilzomib-mediated proteasome inhibition impacted upon proliferation, its effect in IL-6-independent (RPMI 8226, U266) and IL-6-dependent (ANBL-6, KAS-6/1) myeloma cell lines was tested. A dose-dependent decrease in cell viability was found in ANBL-6 and RPMI 8226 cells (Fig. 2A), as well as U266 and KAS-6/1 cells (data not shown), treated continuously with carfilzomib for 24 hours, with a median inhibitory concentration (IC\textsubscript{50}) less than 5 nM in both after 24 hours. This effect was further enhanced at 48 and 72 hours (data not shown). In order to determine whether the observed viability changes were due to induction of apoptosis, MM cell lines were treated continuously with carfilzomib at 5 nM (U266, KAS-6/1) or 10 nM (RPMI 8226, ANBL-6). An apoptosis-specific DNA fragmentation ELISA revealed that low dose carfilzomib induced apoptosis in all cell lines to varying degrees (Fig. 2B).

Pulse treatment for one hour with carfilzomib followed by exposure to drug-free medium also induced a dose-dependent inhibition of proliferation, though higher drug concentrations were necessary (Fig. 2C). This activity was associated with DNA fragmentation (Fig. 2D), and enhanced levels of programmed cell death were also detected by staining with Annexin V, which showed a 2.5-fold increase after a 1 hour pulse with 100 nM carfilzomib in ANBL-6 cells (data not shown).

**Mechanisms of carfilzomib-induced apoptosis.** Initiation of apoptosis can occur through an intrinsic pathway involving cytochrome c release and caspase-9 activation, or an
extrinsic pathway mediated by activation of Fas/caspase-8-dependent signaling, which then converge on a common effector, caspase-3. Bortezomib-induced apoptosis activates both pathways, and we therefore examined whether carfilzomib had similar pro-apoptotic effects. Measurement of caspase activity in ANBL-6 cells pulsed with carfilzomib revealed substantial increases in caspase-8, -9 and –3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours (Fig. 3A). Caspase-9 and –3 activities continued to increase up to 24 hours later, though no discernible increase in caspase-8 activity was found beyond 8 hours. To confirm that caspase activation was necessary for carfilzomib-induced cell death, ANBL-6 cells were treated with caspase inhibitors, followed by a brief pulse of carfilzomib (Fig. 3B). Inhibition of caspase-3, -8, and –9 rescued 95%, 76%, and 94% of ANBL-6 cells, respectively (Fig. 3B), from carfilzomib-mediated growth inhibition. These data indicated that carfilzomib-induced apoptosis occurred through both intrinsic and extrinsic caspase pathways.

A major characteristic of intrinsic caspase-stimulated apoptosis is the loss of mitochondrial trans-membrane potential (ΔΨm) and release of pro-apoptotic proteins, including cytochrome c and second mitochondrial activator of caspses (Smac/DIABLO). To examine whether carfilzomib-mediated apoptosis led to mitochondrial membrane depolarization, ANBL-6 cells were pulsed with 100 nM carfilzomib and stained with the cationic dye, JC-1, and the polarity of the mitochondrial membrane was assessed by flow cytometry. JC-1 undergoes a shift from green to red fluorescence in non-apoptotic cells. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity was decreased to 41% (Q1 + Q2), compared to 75% in vehicle-treated control cells (Fig. 3C). Similar results were obtained in RPMI 8226 cells analyzed using fluorescent microscopy for ΔΨm (data not shown). Formation of the apoptosome, a large multi-subunit molecule, requires the release of
cytochrome c from mitochondria and the inclusion of both cytochrome c and caspase-9 in order to signal to the effector caspase-3.\textsuperscript{26} Cellular fractionation for the cytosolic component and heavy membrane fraction (HMF), including intact and disrupted mitochondria, revealed that a brief pulse with carfilzomib led to cytosolic accumulation of cytochrome c and Smac, and a concomitant decrease of these proteins in the HMF (Fig. 3D).

Pro-apoptotic signaling through JNK and its downstream targets, including c-Jun, plays an important role in cell death due to other proteasome inhibitors.\textsuperscript{27-29} To determine whether JNK activation is important in mediating carfilzomib-induced apoptosis, RPMI 8226 cells were exposed to a pulse of carfilzomib, and JNK activation status was determined. Indeed, brief pulses with carfilzomib led to a significant increase in activated JNK, lasting up to 48 hours (Fig. 3E). Additionally, cleavage of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), a late stage apoptotic event, correlated well with JNK activity levels. In order to study whether c-Jun phosphorylation by activated JNK is important in the apoptotic signaling cascade induced by carfilzomib, ANBL-6 cells were infected with a DN-c-Jun adenovirus, after which the anti-proliferative function of carfilzomib was assessed. Disruption of c-Jun activation led to nearly complete inhibition of the anti-proliferative activity of carfilzomib (Fig. 3F). Similarly, DN-c-Jun suppressed carfilzomib-induced apoptosis in pulse treated ANBL-6 cells, as measured by a 2-fold decrease in caspase-3 activity (Fig. 3G).

**Effects of carfilzomib and bortezomib in MM cell lines.** Bortezomib is approved for the treatment of relapsed/refractory MM patients, where it has been shown to improve survival, even in patients with poor-risk disease, such as those with chromosome 13 deletion.\textsuperscript{10,30} The efficacy of pulse carfilzomib and bortezomib treatment was therefore compared in cell line models of MM (Fig. 4). First, we evaluated the viability of both IL-6-dependent and –
independent cell lines pulse treated with increasing doses of proteasome inhibitor and allowed to recover for 24 hours. Statistically significant (p <0.05) decreases in the viable cell population treated with carfilzomib were observed in ANBL-6, KAS-6/1, H929, and RPMI 8226 cells compared to bortezomib-treated counterparts, indicating an overall trend towards increased sensitivity in myeloma cell lines to carfilzomib (Fig. 4A). Furthermore, JNK phosphorylation was enhanced with carfilzomib treatment compared to bortezomib (Fig. 4B). Comparisons of caspase activity levels also indicated that carfilzomib was more potent than bortezomib in increasing caspase –3, -8, and –9 activity, and did so by 1.5-, 1.8, and 2.0-fold more, respectively, compared to bortezomib (Fig. 4C).

**Carfilzomib effects in patient-derived samples.** Based on the results obtained from MM cell culture models, it was of interest to evaluate the activity of carfilzomib in purified CD138⁺ plasma cells derived from patients. Exposure of such cells to escalating doses of carfilzomib for 24 hours continuously, followed by measurement of the ChT-L activity, revealed that carfilzomib induced a dose-dependent proteasome inhibition (Fig. 5A). Similarly, cellular viability decreased significantly in such plasma cells treated continuously with carfilzomib (Fig. 5B). We then examined whether a brief pulse of carfilzomib had greater anti-proliferative effects compared to a similar pulse of bortezomib. Plasma cells from either bone marrow aspirates or peripheral blood of patients, some with chromosome 13 deletions, were pulsed with 100 nM carfilzomib or bortezomib. Carfilzomib inhibited proliferation to a greater extent than bortezomib by 11 to 70% in eight of nine samples from patients who were clinically bortezomib-naïve (Fig. 5C). However, bortezomib did display increased anti-proliferative efficacy in one sample compared with carfilzomib (Fig. 5C). It is important to note that all
experiments were performed in purified CD138+ plasma cells, and the effect of carfilzomib on other clonal sub-sets of cells is currently unknown.

In addition to activity against multiple myeloma, bortezomib is clinically active against other hematologic malignancies, so we also sought to examine the impact of carfilzomib in other models. Carfilzomib inhibited proliferation and induced apoptosis in purified samples from patients with diffuse large B-cell non-Hodgkin lymphoma (NHL; Fig. 5D), chronic lymphocytic leukemia (CLL; Fig. 5E), and acute myeloid leukemia (AML; Fig. 5F). Inhibition of the ChT-L activity was confirmed in purified CD19+ cells from a patient with B-cell CLL (data not shown), and this ChT-L inhibition correlated well with induction of apoptosis in carfilzomib pulse-treated cells (Fig. 5E). Relative to bortezomib, carfilzomib appeared to show enhanced activity against all of these samples (Fig. 5D-F).

**Carfilzomib and drug-resistance.** The potent activity of carfilzomib led us to evaluate the possibility that it could overcome bortezomib-resistance. Bortezomib-resistant cell lines (BR) were prepared by exposing wild type cells (wt) to increasing dosages of bortezomib over several months until discernible changes in bortezomib-sensitivity were observed. Resistant cell lines displayed significant decreases in their sensitivity to the anti-proliferative effects of bortezomib treatment. For example, ANBL-6.wt cells exposed continuously to 5 nM bortezomib for 24 hours experienced a 78% decrease in the viable cell population, compared to ANBL-6.BR cells, where only a 7% loss of viability was seen, indicating a 4-fold loss of bortezomib sensitivity (Supp. Fig. 1A). Similar results were found in comparisons of RPMI 8226.BR and OPM-2.BR cells with their wild type parentals. ANBL-6.wt and BR cells were then pulse treated with comparable concentrations of carfilzomib or bortezomib, and the anti-proliferative effects were assessed after 24 hours. Resistance to bortezomib did result in some
cross-resistance with carfilzomib, since BR cells were less sensitive than wild-type cells to this irreversible inhibitor (Fig. 6A). However, carfilzomib was more potent at inhibiting proliferation in BR cell lines than bortezomib, with ANBL-6.BR (Fig. 6A), RPMI 8226.BR (Supp. Fig. 1B), and OPM-2.BR (Supp. Fig. 1C) cells exhibiting a 2.0-fold, 1.5-fold, and 2.1-fold increased sensitivity to carfilzomib, respectively. Similarly, in CD138+ plasma cells from a patient who had no clinical benefit after bortezomib therapy, carfilzomib retained the ability to inhibit proliferation (Fig. 6B). Exposure of plasma cells from two patients who both clinically progressed while on bortezomib to carfilzomib showed enhanced cytotoxic effects compared to treatment with bortezomib (Fig. 6C and D).

The ability of carfilzomib to overcome resistance to other anti-myeloma agents was examined in melphalan-, dexamethasone-, and doxorubicin-resistant cell lines (Fig. 6E). Carfilzomib overcame dexamethasone resistance, in that MM1.R cells revealed an IC$_{50}$ of 15.2 nM which, interestingly, was less than the value of 29.3 nM for parental MM1.S cells. Resistance to melphalan also did not impact carfilzomib, since the IC$_{50}$ in RPMI 8226.wt cells was comparable to that in melphalan-resistant 8226.LR5 cells. In contrast, doxorubicin-resistant 8226.Dox40 cells did not respond to carfilzomib, as there was minimal proliferation inhibition at concentrations up to 1000 nM (Supp. Fig. 1D). However, pretreatment with the p-glycoprotein inhibitor verapamil partially overcame this resistance (Fig. 6E), supporting the possibility that carfilzomib may be subject to p-glycoprotein-mediated drug resistance.

Anti-myeloma agents are often used in combinations to enhance their anti-tumor activity, and addition of dexamethasone to bortezomib is one strategy that has shown improved efficacy. To determine whether carfilzomib works in concert with dexamethasone, KAS-6/1 and RPMI 8226 cells were treated simultaneously with both drugs for 24 or 48 hours, respectively. Compared with dexamethasone or carfilzomib alone, the combination
demonstrated a greater anti-proliferative effect (Fig. 6F). Moreover, statistical analysis indicated that a high degree of synergy was present between the two drugs at all concentrations tested in both cell lines (Fig. 6G).
Discussion

The reversible proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma, where it has become one standard of care for relapsed/refractory disease, and is under active investigation as a front-line agent. Combination regimens based on bortezomib may have further enhanced activity, including regimens such as bortezomib with doxorubicin. Such findings have validated the ubiquitin-proteasome pathway both as a target by itself for cancer therapy, and as a rational target to induce chemosensitization, and overcome chemoresistance to conventional agents. Despite these encouraging data, some patients have disease that shows primary resistance, and does not respond to bortezomib therapy. Others develop secondary resistance, and progress after an initial response, or do not respond when they are rechallenged after relapsing from an earlier response to bortezomib. Another proteasome inhibitor, NPI-0052, has already been described that can overcome prior bortezomib resistance, and its irreversible mechanism of inhibition suggested that other inhibitors that block proteasome function irreversibly merited study as well. This led us to evaluate the properties of the epoxomicin-related tetrapeptide carfilzomib, and to determine its potential as an anti-myeloma agent.

Carfilzomib shares structural similarity to epoxomicin. Co-crystal studies revealed that epoxomicin formed a unique 6-atom ring structure with the β5 subunit arising from a two-step process that ultimately led to intramolecular cyclization and morpholino adduction. It is a likely assumption that carfilzomib’s interaction with the proteasome is similar in nature, given the identical keto-epoxide pharmacophore. Carfilzomib was found to specifically target the ChT-L proteasome activity (Fig. 1B) by binding potently and specifically to the β5 constitutive
proteasome and β5i immunoproteasome subunits (Fig. 1C). This resulted in accumulation of ubiquitin-protein conjugates (Fig. 1D) and proteasome substrates (Fig. 1E), as well as inhibition of myeloma cell proliferation (Fig. 2A, C) through induction of programmed cell death (Fig. 2B, D). The molecular sequelae of carfilzomib are similar to those of bortezomib, in that activation of both the intrinsic and extrinsic apoptotic pathways was seen, and these converged on the common effector caspase-3 (Fig. 3A). Caspase inhibitors dramatically blocked carfilzomib-stimulated apoptosis, similar to bortezomib-induced apoptosis (Fig. 3B).23 JNK activation is well characterized in bortezomib-induced apoptosis,37 and we found a similarly marked increase in JNK activity with carfilzomib exposure (Fig 3E). Abrogation of JNK apoptotic signaling cascades with a DN-c-Jun construct correlated with a decrease in carfilzomib-induced apoptosis (Fig. 3G). Lauricella et al., had identical findings with bortezomib treatment in hepatoma cells.27

Interestingly, NPI-0052 activated apoptosis predominantly through a caspase-8-mediated pathway, with little dependence on caspase-9.13 Bortezomib preferentially inhibits the ChT-L activity, as does carfilzomib, while NPI-0052 inhibits the ChT-L, as well as the PGPH and T-L proteases. These findings suggest that proteasome inhibitors targeting predominantly the β5 and/or β5i subunits may trigger dual extrinsic and intrinsic apoptosis pathway activation irrespective of their chemical composition, or their ability to form either reversible or irreversible bonds with the active site threonine. The predominant reliance of NPI-0052 on caspase-8 would therefore seem to be partly related to the interaction of the proteasome active sites with the unique substituents on its bicyclic ring system, which do not induce Bax activation, oligomerization, and mitochondrial insertion. In further dissecting the activity and mechanism of action of proteasome inhibitors, it would therefore be of interest in the future to test agents that specifically target only the PGPH, or only the T-L proteases. Also,
the role of the immunoproteasome in contributing to the activation of distinct apoptotic pathways has not been defined as of yet, but all three classes of proteasome inhibitors, including bortezomib, carfilzomib, and NPI-0052, have been shown to bind and inhibit immunoproteasome-specific subunits. The use of specific immunoproteasome inhibitors that have been recently identified may be of help in determining the extent of the immunoproteasome dependency to cellular survival.

Proteasome inhibition with carfilzomib resulted in potent anti-proliferative and pro-apoptotic effects in myeloma cell lines (Fig. 2), and in patient-derived models of myeloma (Fig. 5). Presence of deletion of chromosome 13 identifies a poor prognosis sub-group of patients with myeloma who have good benefits with bortezomib-based therapy. Several of the cell lines and patient samples tested herein also harbored this cytogenetic abnormality, and responded well to carfilzomib pre-clinically. This suggests the possibility that proteasome inhibitors as a class may be especially effective in this population, though larger prospective studies are needed to verify these findings for bortezomib, and carfilzomib is just entering clinical trials. Carfilzomib also showed evidence of activity against malignant cells from patients with NHL, and both AML and CLL, suggesting other possible areas for future clinical development. Stapnes et al. also found that carfilzomib potently inhibited proliferation and induced apoptosis in CD34+ cells from patients with AML.

One notable finding is that carfilzomib was more potent than bortezomib in proteasome inhibitor-naïve models (Fig. 3). Also of importance, carfilzomib overcame both primary and secondary resistance to bortezomib in both cell line models and clinical samples (Fig. 6). The mechanism by which this occurs has not yet been elucidated, but previous studies with NPI-0052 suggested that it was this agent’s ability to block several proteasome proteases that allowed it to overcome bortezomib resistance. Since carfilzomib has a similar property in
overcoming resistance, but predominantly binds only the ChT-L subunit, our studies suggest that it may be the irreversibility of agents such as NPI-0052 and carfilzomib that confers this attractive property. If true, this suggests a possible mechanism, since one characteristic of cells that express primary resistance to bortezomib is the over-expression of proteasome subunits, and other ubiquitin-proteasome pathway proteins.\textsuperscript{41-43} It may be that irreversible drugs would require the cell to synthesize and reassemble new proteasomes to recover their proteolytic capacity. Since this would take longer than recovery from reversible inhibitors, that in part would occur by dissociation of bortezomib without the need for new protein synthesis, irreversible inhibitors would provide a longer-lasting inhibition. Such prolonged inhibition could result in enhanced efficacy, or in the ability to overcome the cell’s attempt at resistance by over-production of proteasomes. Additionally, the ability of carfilzomib to overcome bortezomib resistance does not seem to be linked to cellular transport mechanisms as the rate of onset of proteasome inhibition does not differ greatly in a variety of cell types exposed to carfilzomib and bortezomib (data not shown). However, it is important to note that these studies were conducted in proteasome inhibitor-naïve cells. Further studies will be needed to elucidate the contribution of these possibilities, or if some different pathway is responsible for the ability to partially overcome bortezomib-resistance. These should be helped by the development of bortezomib-resistant myeloma cell models such as those described herein, which have not previously been reported.

Taken together, the above data provide a strong rationale for clinical evaluation of the proteasome inhibitor carfilzomib in patients with relapsed and refractory myeloma. One concern would be that the irreversible mechanism of action of carfilzomib could result in enhanced toxicities of the kind described for bortezomib, such as cytopenias, gastrointestinal events, constitutional symptoms, and peripheral neuropathy. It certainly is also possible that
this agent’s mechanism of action, and likely different clinical pharmacokinetics and pharmacodynamics, could result in new, here-to-fore uncharacterized dose-limiting toxicities. Phase I studies of carfilzomib are currently underway using two different schedules, however, and to date no untoward toxicities have been reported, and anti-tumor activity is beginning to be seen.44 This agent’s ability to overcome bortezomib resistance pre-clinically suggests that it may provide another therapeutic option for patients whose disease has progressed through bortezomib, or for those who have had responses of very brief duration. Also, carfilzomib in combination with dexamethasone leads to a synergistic anti-proliferative effect, indicating that rationally-designed combination regimens may further improve the therapeutic efficacy of carfilzomib in the relapsed/refractory and possibly front-line myeloma settings.
Acknowledgements

R.Z.O., a Leukemia & Lymphoma Society Mansbach Foundation Scholar in Clinical Research, and a Jefferson Pilot fellow in Academic Medicine, would like to acknowledge support from the Leukemia & Lymphoma Society (6096-07), the Multiple Myeloma Research Foundation, and the National Cancer Institute (RO1 CA102278). D.J.K. was supported by the National Institute of Health (T32 CA 09156). D.J.K. designed and performed the majority of the research and wrote the manuscript. K.D.S., C.M.S., S.D.D., and M.K.B provided reagents, helped with data analysis, and performed the ELISA experimentation. J.S.S. and P.M.V. consented patients and obtained their samples. Q.C. and P.M.V. were essential for helping with patient sample purifications. F.B.L. provided vital reagents and contributed to data analysis. R.Z.O. supervised all the research completed herein and offered valuable suggestions and manuscript editing.

Conflict of Interest Disclosure: K.D.S., C.M.C., S.D.D., and M.K.B. are employees of Proteolix, Inc., and receive stock options as part of their employment.

Abbreviations

AML, acute myeloid leukemia; BR, bortezomib resistant; ChT-L, chymotrypsin-like proteasome activity; CLL, chronic lymphocytic leukemia; DN, dominant negative; DOR, degree of resistance; ELISA, enzyme-linked immunosorbent assay; HMF, heavy membrane fraction; IL, interleukin; JNK, c-Jun-N-terminal kinase; IC$_{50}$, median inhibitory concentration; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PARP, poly(adenosine diphosphate [ADP]-ribose) polymerase; PBS, phosphate-buffered saline; PGPH, post-glutamyl peptide

Page 23
hydrolyzing, or caspase-like proteasome activity; Smac, Second mitochondrial activator of caspases; T-L, trypsin-like activity; VS, vinyl sulfone; wt, wild type. In addition, standard one-letter abbreviations are used for peptide amino acid residues.
References


Figure Legends

Figure 1. Inhibition of the proteasome by carfilzomib.

(A), Structure of epoxomicin and carfilzomib. (B), Quantitative representation of the in vitro inhibition of the 20S proteasome catalytic activities in ANBL-6 cellular lysates (10 µg/reaction) in the absence or presence of carfilzomib with fluorogenic peptide substrates for the proteasomal ChT-L, PGPH, and T-L activity, as indicated, followed by the measurement of free 7-amido-4-methylcoumarin (AMC) groups. (C), In cellulo measurement using ELISA techniques of the 20S proteasome subunit targets of carfilzomib in cell extracts from ANBL-6 cells pulse treated for 1 hour with carfilzomib. (D), Competitive binding experiment in ANBL-6 cells between carfilzomib (5 hour pre-treatment) followed by VS-L3-AHx3-danyls (2 hours) to determine the in cellulo specificity of carfilzomib to individual proteasome catalytic subunits. Western blot analysis of the accumulation of ubiquitinated substrates (E) and pro-apoptotic Bax (F) after 1 hour pulse exposure to carfilzomib (100 nM) in RPMI 8226 cells, followed by 24 and 48 hour recovery times. Actin was used as a loading control.

Figure 2. Inhibition of proliferation and induction of apoptosis by carfilzomib.

IL-6-independent RPMI 8226 and IL-6-dependent ANBL-6 multiple myeloma cells (2 x 10⁴) were treated continuously (A) or pulsed for 1 hour (C) with increasing concentrations of carfilzomib. Cellular viability was determined at 24 hours using the water-soluble tetrazolium salt WST-1. IL-6-dependent (ANBL-6, KAS-6/1) and –independent (RPMI 8226, U266) myeloma cells were continuously exposed (B) or pulsed (D) with carfilzomib for 1 hour and allowed to recover for 24 hours. Programmed cell death was then evaluated using a DNA
fragmentation enzyme-linked immunosorbent assay. Results are expressed as a fold-increase of DNA fragmentation over DMSO control.

**Figure 3. Molecular events associated with exposure to carfilzomib.**

(A), ANBL-6 cells were exposed to a pulse of 100 nM carfilzomib, bortezomib, or vehicle (Veh) control and allowed to recover for 8 or 24 hours. Cellular lysates (30 µg/reaction) were incubated with 40 µM fluorogenic substrates specific for caspase-3, caspase-8, and caspase-9. Results are expressed as fold relative fluorescence units over DMSO control. (B), ANBL-6 (2 x 10⁴ cells/reaction) were pre-treated for 20 hours with caspase-3-, -8-, and –9-specific inhibitors, a negative control, a pan-caspase inhibitor, or no inhibitor (-), followed by a 1 hour pulse with 100 nM carfilzomib. Fresh media containing caspase inhibitors was then added and cellular proliferation was determined after a 24 hour recovery period. Data were expressed as percent inhibition compared to vehicle (DMSO) controls. (C), Carfilzomib induces depolarization of mitochondria. The fluorescent shift of the JC-1 cationic dye from cytosol (green fluorescence) to mitochondria (red fluorescence) in live cells was analyzed by flow cytometry in ANBL-6 cells pulsed with 100 nM carfilzomib (Q1: red fluorescence; Q2: red and green fluorescence; Q3: green fluorescence). (D), ANBL-6 cells treated for 1 hour with 100 nM carfilzomib were subjected to centrifugal cellular fractionation into the cytosolic fraction and heavy membrane fraction (HMF) that includes mitochondria. Release of cytochrome c and Smac from the mitochondria was assessed by Western blot. Cox II, an intra-mitochondrial protein, was used as a control. Whole cell extract (WCE) was monitored as a control for protein expression. (E), Western blot analysis for the phosphorylation of JNK (i.e. activated JNK) and cleavage of PARP in RPMI 8226 cells, which were pulsed with 100 nM carfilzomib and allowed to recover for the indicated time periods. HSC-70 was used as a loading control.
To determine whether abrogation of JNK signaling through c-Jun affects carfilzomib’s anti-proliferative and pro-apoptotic action, ANBL-6 cells (2 x 10^4/well) were infected with DN-c-Jun adenovirus for 24 hours, followed by addition of 100 nM pulse with carfilzomib. Cellular growth was assessed using the WST-1 reagent (F) and apoptosis was measured by DNA fragment production (G).

**Figure 4. Activity of carfilzomib and bortezomib against myeloma models.**

(A), Several MM cell lines were treated with a 1 hour pulse of increasing concentrations of carfilzomib or bortezomib. After 24 hours the number of live cells was determined with a WST-1 assay. (B), Activation of the stress response in RPMI 8226 cells pulse treated for 1 hour with proteasome inhibitors and allowed to recover for the indicated time points. Protein expression levels of activated JNK were examined after treatment with carfilzomib or bortezomib. (C), ANBL-6 cells were exposed to a 1 hour pulse of 100 nM carfilzomib or bortezomib and allowed to recover for 8 hours. Cellular lysates (30 µg/reaction) were then incubated with 40 µM fluorogenic substrates specific for caspase-3, caspase-8, and caspase-9 activity. Results are expressed as fold relative fluorescence units over DMSO control and determined as described in Figure 1.

**Figure 5. Activity of carfilzomib and bortezomib in patient samples.**

(A), Purified plasma cells were continuously treated with increasing doses of carfilzomib for 24 hours. Cells were then lysed and the ChT-L activity was determined (10 µg/reaction). (B), CD138^+ cells were treated with continuous exposure to the indicated concentrations of carfilzomib, followed by a WST-1 cell viability assay. (C), Purified plasma cells were pulse treated with 100 nM carfilzomib or bortezomib, followed by recovery in drug-free media for 24
hours. WST-1 was used to assess proliferation. Several of the samples are from patients with chromosome 13 deletions (MM-13, MM-15, MM-17, MM-20, and MM-23). Results are expressed as the percent (%) inhibition of proliferation of carfilzomib-treated cells relative to bortezomib-treated cells, which were set at 0, with a positive result indicating the amount of enhanced anti-proliferative activity of carfilzomib over that of bortezomib. (D), Pulse carfilzomib and bortezomib exposure in an NHL patient sample and determination of anti-proliferation activity by WST-1 assay. (E), Flow cytometric analysis of carfilzomib- versus bortezomib-induced specific apoptosis in patient-derived CD19+ CLL B-cells. Patient cells were pulsed (100 nM) for 1 hour with the indicated drug, and allowed to recover for 24 hours. Apoptosis was assessed in cells stained with Annexin V/TO-PRO-3/anti-CD-19. Specific apoptosis is shown in the CD-19+ gated population relative to vehicle controls. (F), AML cells from a patient with progressive disease after multiple chemotherapeutic treatments were pulsed for 1 hour with 100 nM carfilzomib or bortezomib, or continuously treated with 1 µM doxorubicin (Dox). Apoptosis was measured by a DNA fragmentation ELISA assay, and expressed as fold induction over DMSO control in CD-33+ cells purified from PBMC. Data are mean ± standard error (SE) of each experiment performed in triplicate.

**Figure 6. Carfilzomib and chemotherapeutic-resistance.**

(A), ANBL-6.BR, along with their wild type counterparts, were pulsed with carfilzomib for 1 hour, and proliferation was assessed using the WST-1 reagent after a 24 hour recovery period. The degree of resistance (D.O.R.) to bortezomib was computed by comparing the IC50’s of bortezomib-sensitive and -resistant cells. (B), CD138+ cells from a MM patient with a chromosome 13 deletion who did not have a clinical response to bortezomib were treated with continuous exposure to the indicated concentrations of carfilzomib or bortezomib for 24 hours.
in triplicate, followed by measurement of proliferation with the WST-1 assay. (C), CD138⁺ cells from a MM patient who progressed while on bortezomib treatment were exposed to increasing concentrations of carfilzomib or bortezomib for 24 hours prior to assessment for cellular proliferation. (D), CD138⁺ plasma cells from a patient who progressed on bortezomib were exposed to continuous and pulse treatments with equivalent concentrations of carfilzomib and bortezomib, followed by a WST-1 cellular proliferation assay. (E), Carfilzomib’s activity was assessed in wild type (MM1.S and RPMI 8226.wt), melphalan-resistant (8226.LR5), dexamethasone-resistant (MM1.R), and doxorubicin-resistant (8226.Dox40) myeloma cells. 8226.Dox40 cells were also pretreated for 24 hours with the p-glycoprotein inhibitor verapamil (15 µM). Cells were pulsed for 1 hour with increasing concentrations of carfilzomib, and the IC₅₀ of proliferation was assessed after a 24 hour recovery. (F), RPMI 8226 cells were treated continuously with 5 nM carfilzomib and 10 µM dexamethasone for 48 hours to determine the effect of this combined therapy against cellular proliferation. (G), Combination indices of RPMI 8226 and KAS-6/1 cells treated for 48 and 24 hours, respectively, with the indicated concentrations of carfilzomib and dexamethasone. Data were analyzed using Calcusyn (v.2) software from BioSoft®. The combination index (CI) is a quantitative measure of the degree of drug interaction, with a CI < 1 indicating synergy, a CI = 1 indicating additive effects, and a CI > 1 indicating antagonist (CI > 1).
Figure 1

A. Epoxomicin
B. % 2OS Activities (RFU)
C. Carfilzomib concentration (μM)
D. 10 μM VS-L3-AHx3-danys1
E. Veh 24 48 h
F. Veh 24 48 h
Figure 2

A.

B.

C.

D.
Figure 3

A. 

B. 

C. 

D. 

E. 

F. 

G.
Figure 4

A. % Proliferation

B. Carfilzomib Bortezomib

C. Fold Caspase Induction
Figure 5

A. % ChT-L Activity

B. % Proliferation

C. % Inhibition of proliferation (relative to Bortezomib)

D. % Proliferation

E. % Specific Apoptosis (relative to Vehicle)

F. Fold DNA fragmentation

Legend:
- MM-17
- NHL-01
- MM-03
- CLL-05
- AML-03

No relevant content extracted from the image.
Figure 6

A. Degree of Resistance to Bortezomib

B. % Proliferation

C. % Proliferation

D. % Proliferation

E. Median Inhibitory Concentration (IC₅₀)

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>IC₅₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>MM1.S</td>
<td>29.3 nM</td>
</tr>
<tr>
<td>MM1.R</td>
<td>15.2 nM</td>
</tr>
<tr>
<td>RPMI 8226.wt</td>
<td>89.9 nM</td>
</tr>
<tr>
<td>8226.LR5</td>
<td>83.3 nM</td>
</tr>
<tr>
<td>8226.Dox40</td>
<td>$&gt;1000$ nM</td>
</tr>
<tr>
<td>8226.Dox40 + Verapamil</td>
<td>829 nM</td>
</tr>
</tbody>
</table>

F. % Proliferation

G. Combination Indices

<table>
<thead>
<tr>
<th>Combination</th>
<th>RPMI 8226</th>
<th>KAS-6/1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.1 0.2 0.1</td>
<td>0.1 0.3 0.6</td>
</tr>
<tr>
<td>2.5</td>
<td>0.3 0.3 0.3</td>
<td>0.2 0.3 0.7</td>
</tr>
<tr>
<td>5</td>
<td>0.5 0.5 0.5</td>
<td>0.9 0.5 0.6</td>
</tr>
<tr>
<td>10</td>
<td>0.8 0.9 0.9</td>
<td>0.1 0.2 0.5</td>
</tr>
</tbody>
</table>
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijis W. B. van Leeuwen, Asher A. Chanan-Khan and Robert Z. Orlowski